PreMD says cholesterol trial supports primary objective

By Elaine Rigoli

Tampa, Fla., July 12 - PreMD Inc. announced interim results from the Prepare (Prevu - Predicts Atherosclerosis Risk and Events) study, which is being conducted in the life-insurance industry with selected U.S. life insurers using Prevu* LT skin sterol test.

"The preliminary data on Prevu* LT demonstrates statistically significant relationships and is supportive of the study's primary objective. As a result, the study will conclude at the end of this month with approximately 13,000 subjects enrolled. We are moving quickly to complete full data collection and analysis from the study and are working with McNeil Consumer Healthcare to finalize the regulatory and marketing strategies for Prevu* LT in 2006," president and chief executive officer Brent Norton said in a news release.

Prevu* non-invasively measures the amount of cholesterol (sterol) that has accumulated in the skin tissues, as opposed to blood.

PreMD, based in Toronto, focuses on predictive medicine.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.